3 High-Growth Small-Cap Stocks to Buy Right Now

Given their excellent growth prospects, these three small-cap stocks can deliver superior returns over the next three years.

| More on:
Growing plant shoots on coins

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Small-cap stocks have high-growth potential and could deliver superior returns in the long run. However, these stocks are highly susceptible to market volatilities and are riskier. So, investors with higher risk-tolerance capacity can buy the following three stocks to earn superior returns over the next three years.

Aurora Cannabis

Despite the continued weakness in the cannabis space, I have picked Aurora Cannabis (TSX:ACB)(NYSE:ACB) as my first pick due to the expanding cannabis market due to its growing medical usages and increased legalization. The company had also posted an improved fourth-quarter performance last month, with its adjusted EBITDA losses and cash burn falling year over year.

Meanwhile, Aurora Cannabis has acquired around 20% of the Canadian medical cannabis market while enjoying a higher gross margin of 60%. So, the company is planning to allocate more resources to the segment to increase its market share further. It is also expanding its presence in the international market through new product launches, innovation, and strengthening its supply chain.

Additionally, Aurora Cannabis has planned to launch higher-THC content premium products in the recreational cannabis space to boost its sales and margins. Meanwhile, the company has also taken several cost-reducing initiatives, which can deliver $60-$80 million of savings over the next 18 months. So, given its healthy growth prospects and cheaper valuation, I am bullish on Aurora Cannabis.

Savaria

With returns of around 39% this year, Savaria (TSX:SIS) has outperformed the broader equity markets. Its strong performance in the first six months and the acquisition of Handicare appear to have driven its stock price higher. Despite the steep rise, the mobility and accessibility solutions provider still trades at an attractive forward price-to-sales multiple of 1.8.

Meanwhile, the demand for Savaria’s products and solutions could increase in the coming years amid the growing aging population and rising income levels. Besides, the acquisition of Handicare has added new production facilities, expanded its product offering, increased its geographical presence, provided cross-selling opportunities, and diversified its revenue stream.

Further, Savaria’s management had raised its monthly dividends by 4.17% to $0.0417 per share, with its forward yield standing at 2.49%. So, given its healthy growth prospects, attractive valuation, and steady monthly dividends, I am bullish on Savaria. Analysts also look bullish on Savaria, with all the eight analysts issuing a buy rating.

Cineplex

Although Cineplex (TSX:CGX) has witnessed a strong buying this year, it is still trading at a significant discount from its pre-pandemic levels, providing an excellent buying opportunity. With the easing of restrictions, the company has reopened all its screens from July 17. Its subscription programs, enhanced safety measures, and growing food delivery services could boost its financials in the coming quarters. Also, the company could benefit from the widespread vaccination, pent-up demand, and new movie releases.

Additionally, Cineplex has taken several cost-reduction measures and strengthened its liquidity positions, which could help it bounce back quickly. Meanwhile, it is also trading at an attractive valuation, with its forward price-to-sales multiple standing at 0.6. So, given the improving business environment and its cheap valuation, I expect Cineplex to deliver superior returns over the next three years. Meanwhile, analysts favour a hold rating, with four of the seven analysts issuing a “hold” rating.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends CINEPLEX INC. and Savaria Corp. Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »